AllianceBernstein
RNAC icon

AllianceBernstein’s Cartesian Therapeutics RNAC Stock Holding History

AllianceBernstein’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Buy
22,115
+9,350
+73% +$69.3K ﹤0.01% 3229
2026
Q1 		$92K Hold
12,765
– – ﹤0.01% 3164
2025
Q4 		$92K Hold
12,765
– – ﹤0.01% 3177
2025
Q3 		$130K Buy
12,765
+870
+7% +$9.78K ﹤0.01% 3151
2025
Q2 		$124K Buy
+11,895
New +$127K ﹤0.01% 3141
2024
Q2 		– Sell
-576
Closed -$11.2K – 3288
2024
Q1 		$11.2K Hold
576
– – ﹤0.01% 3132
2023
Q4 		$11.9K Hold
576
– – ﹤0.01% 3175
2023
Q3 		$18.3K Sell
576
-181
-24% -$6.05K ﹤0.01% 3173
2023
Q2 		$25.4K Buy
+757
New +$27.1K ﹤0.01% 3151
2022
Q2 		– Sell
-3,690
Closed -$136K – 3359
2022
Q1 		$136K Buy
3,690
+10
+0.3% +$626 ﹤0.01% 3073
2021
Q4 		$360K Hold
3,680
– – ﹤0.01% 2880
2021
Q3 		$459K Hold
3,680
– – ﹤0.01% 2788
2021
Q2 		$461K Buy
3,680
+947
+35% +$113K ﹤0.01% 2841
2021
Q1 		$371K Sell
2,733
-550
-17% -$68.3K ﹤0.01% 2816
2020
Q4 		$298K Sell
3,283
-1,680
-34% -$146K ﹤0.01% 2853
2020
Q3 		$369K Sell
4,963
-827
-14% -$63.4K ﹤0.01% 2697
2020
Q2 		$493K Buy
+5,790
New +$525K ﹤0.01% 2624

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein's RNAC Position: Q2 2026 in Review

AllianceBernstein increased its Cartesian Therapeutics (RNAC) stake by 73% in Q2 2026, buying an estimated $69.3K and bringing the position to 22,115 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #3229.

AllianceBernstein first reported a position in RNAC in Q2 2020 and has held it in 17 quarters since. The position peaked at $493K in Q2 2020. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • AllianceBernstein held 22,115 shares of Cartesian Therapeutics worth $136K as of Q2 2026.
  • AllianceBernstein bought 9,350 Cartesian Therapeutics shares in Q2 2026, an estimated $69.3K.
  • Cartesian Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3229 holding.
  • AllianceBernstein first reported a position in Cartesian Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • AllianceBernstein's Cartesian Therapeutics position peaked at $493K in Q2 2020.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.